Advertisement
UK markets closed

  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     

  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     

  • AIM

    745.67
    +0.38 (+0.05%)
     

  • GBP/EUR

    1.1607
    -0.0076 (-0.65%)
     

  • GBP/USD

    1.2370
    -0.0068 (-0.55%)
     

  • Bitcoin GBP

    51,701.71
    +1,303.73 (+2.59%)
     

  • CMC Crypto 200

    1,371.97
    +59.34 (+4.52%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • DOW

    37,986.40
    +211.02 (+0.56%)
     

  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     

  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     
Property:

11 beautiful homes with glorious garden rooms

Investing in a home with a garden room will enable you to enjoy your outside space whatever the weather

Global $5.1 Bn Migraine Drugs Market 2020-2024 by Mode of Administration, Treatment Class & Regions

Research and Markets
·5-min read

Dublin, Oct. 27, 2020 (GLOBE NEWSWIRE) -- The "Global Migraine Drugs Market (by Mode of Administration, Treatment Class & Regions): Insights and Forecast with Potential Impact of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering.

The global migraine market is expected to reach US$5.10 billion in 2024, growing at a CAGR of 3.7%, for the duration spanning 2020-2024.

The factors such as growing female population, increasing cigarette consumption, increasing pharmaceutical R&D expenditures, accelerating economic growth, increasing healthcare spending, increasing stress levels, unmet medical needs and prevalence of migraine at high rates would drive the growth of the market. However, the market growth would be challenged by the adverse effect of drugs, lack of proper diagnosis, increased preferences for alternative options, regulatory challenges and high cost associated. A few notable trends include growth in pharmaceutical & biotech merger & acquisition, progressing CGRP targeting drug pipeline, branded acute treatment for episodic migraine, growing awareness regarding migraine and its therapeutics and development of additional migraine therapeutics.

The global migraine market holds a lucrative growth opportunity for the coming future due to the high prevalence rate of migraine among people. Migraine market is expected to witness the advent of first-in-class novel migraine therapeutics, especially meant for patients who are unresponsive to triptans or ones at risk of cardiovascular disorders.

A considerable amount of funds are being invested in the research and development of new migraine drugs, in order to make such therapeutics available in the market. A number of drugs are under late-stage clinical process and some therapeutics are registered for the FDA approval. Launches of new migraines drugs would thereby help the migraine market to grow globally in the coming years.

The fastest-growing regional market is North America, due to the presence of well-established healthcare infrastructure as well as major pharmaceutical players. Increased retail sales of triptans and ergot alkaloids, demanded by the people with acute migraine conditions for the abortive purpose, helped the market to grow at a considerable pace in the region. Europe and the Asia Pacific also secured considerable shares in the migraine market, owing to the high prevalence rate of migraine, along with the increased programmes of collaboration and partnership in the pharmaceutical sector.

Further, the sudden outbreak of COVID-19 would trigger stress levels among people, due to the implementation of the lockdown measures, which would elevate the risk of migraine among them and thereby is expected to accelerate the growth of the global migraine market in coming years.

ADVERTISEMENT

The competitive landscape of the market, along with the company profiles of leading players (Johnson & Johnson, Novartis AG, Merck & Co., AbbVie Inc., Bristol-Myer Squibb and Amgen AG) are also presented in detail.

Key Target Audience:

  • Monoclonal Antibodies Manufacturers

  • Pharmaceuticals and Biopharmaceutical Firms

  • End Users (Hospitals and Research Institutes)

  • Investment Banks

  • Healthcare and Medical Consultants

  • Government Bodies & Regulating Authorities

Key Topics Covered:

1. Overview
1.1 Migraine
1.2 Types of Migraine
1.3 Stages of Migraine
1.4 Diagnosis Procedures
1.5 Migraine Treatment
1.6 CGRP - A New Era of Migraine Treatment

2. Impact of COVID-19
2.1 Rise in Stress Level
2.2 Growth in Government Spending on Healthcare
2.3 Increase in Alcohol Consumption
2.4 Impact of Excessive Use of Hand Sanitizers

3. Global Market Analysis
3.1 Global Migraine Drugs Market by Value
3.2 Global Migraine Drugs Market Forecast by Value
3.3 Global Migraine Drugs Market by Mode of Administration
3.3.1 Global Oral Migraine Drugs Market by Value
3.3.2 Global Oral Migraine Drugs Market Forecast by Value
3.3.3 Global Injectable Migraine Drugs Market by Value
3.3.4 Global Injectable Migraine Drugs Market Forecast by Value
3.4 Global Migraine Drugs Market by Treatment Class
3.4.1 Global Abortive Migraine Drugs Market by Value
3.4.2 Global Abortive Migraine Drugs Market Forecast by Value
3.4.3 Global Preventative Migraine Drugs Market by Value
3.4.4 Global Preventative Migraine Drugs Market Forecast by Value
3.5 Global Migraine Drugs Market by Regions

4. Regional Market
4.1 North America
4.1.1 North America Migraine Drugs Market by Value
4.1.2 North America Migraine Drugs Market Forecast by Value
4.1.3 North America Migraine Drugs Market by Region
4.1.4 The U.S. Migraine Drugs Market by Value
4.1.5 The U.S. Migraine Drugs Market Forecast by Value
4.2 Europe
4.3 Asia Pacific
4.4 ROW

5. Market Dynamics
5.1 Growth Drivers
5.1.1 Growing Female Population
5.1.2 Increasing Cigarette Consumption
5.1.3 Increasing Pharmaceutical R&D Spending
5.1.4 Accelerating Economic Growth
5.1.5 Increasing Healthcare Spending
5.1.6 Increasing Stress Levels
5.1.7 Unmet Medical Needs
5.1.8 Prevalence of Migraine at High Rate
5.2 Key Trends and Developments
5.2.1 Growth in Pharmaceutical and Biotech Merger & Acquisition
5.2.2 Progressing CGRP - Targeting Drug Pipeline
5.2.3 Branded Acute Treatment for Episodic Migraine
5.2.4 Growing Awareness about Migraine and its Treatment
5.2.5 Development of Additional Migraine Therapeutics
5.3 Challenges
5.3.1 Adverse Effects of Drugs
5.3.2 Lack of Proper Diagnosis
5.3.3 Increased Preference for Alternative Therapies
5.3.4 Regulatory Challenges
5.3.5 High Cost Associated

6. Competitive Landscape
6.1 Global Market
6.1.1 Key Players - Revenue Comparison
6.1.2 Key Players - R&D Expenditure Comparison
6.1.3 Key Players - Market Capitalization Comparison
6.2 The U.S. Market
6.2.1 Key Players - The U.S. CGRP Drugs for Episodic Migraine Market Penetration Forecast
6.2.2 Key Players - The U.S. CGRP Drugs for Chronic Migraine Market Share Forecast

7. Company Profiles

  • AbbVie Inc.

  • Amgen AG

  • Bristol-Myer Squibb

  • Eli Lilly and Company

  • Johnson & Johnson

  • Lundbeck

  • Merck & Co.

  • Novartis AG

For more information about this report visit https://www.researchandmarkets.com/r/dwh810

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900